Literature DB >> 19750054

Classification and pharmacological management of obesity.

Sarah R Erlanger, Emily A Henson.   

Abstract

Entities:  

Year:  2008        PMID： 19750054      PMCID： PMC2730799     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  8 in total

1.  Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks.

Authors:  Kishore M Gadde; David B Allison
Journal:  Circulation       Date:  2006-08-29       Impact factor: 29.690

2.  Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery.

Authors:  Lars Sjöström; Anna-Karin Lindroos; Markku Peltonen; Jarl Torgerson; Claude Bouchard; Björn Carlsson; Sven Dahlgren; Bo Larsson; Kristina Narbro; Carl David Sjöström; Marianne Sullivan; Hans Wedel
Journal:  N Engl J Med       Date:  2004-12-23       Impact factor: 91.245

Review 3.  Bariatric surgery: an overview of obesity surgery.

Authors:  Alan Matarasso; Mitchell S Roslin; Marina Kurian
Journal:  Plast Reconstr Surg       Date:  2007-04-01       Impact factor: 4.730

4.  Obesity: preventing and managing the global epidemic. Report of a WHO consultation.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  2000

Review 5.  Obesity: new perspectives and pharmacotherapies.

Authors:  Kerri L Palamara; Harriette R Mogul; Stephen J Peterson; William H Frishman
Journal:  Cardiol Rev       Date:  2006 Sep-Oct       Impact factor: 2.644

6.  Prevalence of overweight and obesity in the United States, 1999-2004.

Authors:  Cynthia L Ogden; Margaret D Carroll; Lester R Curtin; Margaret A McDowell; Carolyn J Tabak; Katherine M Flegal
Journal:  JAMA       Date:  2006-04-05       Impact factor: 56.272

7.  Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.

Authors:  A Gokcel; Y Gumurdulu; H Karakose; E Melek Ertorer; N Tanaci; N BascilTutuncu; N Guvener
Journal:  Diabetes Obes Metab       Date:  2002-01       Impact factor: 6.577

8.  Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.

Authors:  Arne Astrup; Sten Madsbad; Leif Breum; Thomas J Jensen; Jens Peter Kroustrup; Thomas Meinert Larsen
Journal:  Lancet       Date:  2008-10-22       Impact factor: 79.321
  8 in total
  1 in total

1.  Adiposity Is a Key Correlate of Circulating Fibroblast Growth Factor-21 Levels in African Males with or without Type 2 Diabetes Mellitus.

Authors:  Fredirick L Mashili; Kaushik Ramaiya; Janet Lutale; Marina Njelekela; Filbert Francis; Juleen Zierath; Anna Krook
Journal:  J Obes       Date:  2018-09-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.